IOL Chemicals and Pharmaceuticals Limited
NSE: IOLCP · Pharmaceuticals
Snapshot
Unlock IOL Chemicals and Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
IOL Chemicals and Pharmaceuticals Limited is a manufacturer of active pharmaceutical ingredients (APIs) and specialty industrial chemicals. The company serves a diverse range of sectors including pharmaceuticals, food processing, textiles, and packaging.
Business Model
The company generates revenue through the large-scale production and sale of APIs, notably ibuprofen, and specialty chemicals such as ethyl acetate and iso butyl benzene. It operates as both a domestic supplier and an international exporter.
Growth Outlook
Growth is driven by the expansion of its API portfolio and the sustained demand for its specialty chemical intermediates across multiple industrial applications.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to export restrictions.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and petrochemical derivatives can significantly impact profit margins.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate volatility which may affect its international competitiveness and earnings.
- Commodity Price Sensitivity. The specialty chemicals segment is susceptible to cyclical demand and price pressures within the global industrial chemical market.
Start your research today
Unlock AI insights, financials, peers and live data on IOL Chemicals and Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,751 Cr
TTM · consolidated
NET PROFIT
₹203 Cr
TTM · consolidated
EPS
₹6.92
TTM · consolidated
RETURN ON EQUITY
11.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.9%
TTM · consolidated
P/E
26.0×
Q2 FY27 · consolidated
EV/EBITDA
14.1x
Q2 FY27 · consolidated
EBITDA MARGIN
13.9%
TTM · consolidated
NET PROFIT MARGIN
8.2%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
IOL Chemicals and Pharmaceuticals LimitedIOLCP | ₹5,215 Cr | 26.0× | 14.08 | 26.8% | 13.9% | 11.1% | 14.9% | +94.8% |
Sun Pharma Advanced Research Company LimitedSPARC | ₹5,726 Cr | 3.6× | 3.82 | 2855.8% | 86.0% | 282.4% | 235.1% | +29.5% |
Senores Pharmaceuticals Ltd.SENORES | ₹5,222 Cr | 36.5× | 22.75 | 39.7% | 34.1% | 15.1% | 18.3% | +45.2% |
Orchid Pharma LimitedORCHPHARMA | ₹5,009 Cr | 526.3× | 80.57 | 10.8% | 7.1% | 0.7% | 1.5% | +16.7% |
SMS Pharmaceuticals LimitedSMSPHARMA | ₹4,789 Cr | 44.9× | 28.01 | 10.2% | 20.3% | 14.4% | 15.5% | +76.5% |
Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,727 Cr | 140.0× | 57.66 | 17.5% | 48.8% | 18.2% | 19.8% | -20.5% |
As of Q2 FY27
Financials
IOL Chemicals and Pharmaceuticals Limited
NSE: IOLCP · Pharmaceuticals
Snapshot
Unlock IOL Chemicals and Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
IOL Chemicals and Pharmaceuticals Limited is a manufacturer of active pharmaceutical ingredients (APIs) and specialty industrial chemicals. The company serves a diverse range of sectors including pharmaceuticals, food processing, textiles, and packaging.
Business Model
The company generates revenue through the large-scale production and sale of APIs, notably ibuprofen, and specialty chemicals such as ethyl acetate and iso butyl benzene. It operates as both a domestic supplier and an international exporter.
Growth Outlook
Growth is driven by the expansion of its API portfolio and the sustained demand for its specialty chemical intermediates across multiple industrial applications.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to export restrictions.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and petrochemical derivatives can significantly impact profit margins.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate volatility which may affect its international competitiveness and earnings.
- Commodity Price Sensitivity. The specialty chemicals segment is susceptible to cyclical demand and price pressures within the global industrial chemical market.
Start your research today
Unlock AI insights, financials, peers and live data on IOL Chemicals and Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,751 Cr
TTM · consolidated
NET PROFIT
₹203 Cr
TTM · consolidated
EPS
₹6.92
TTM · consolidated
RETURN ON EQUITY
11.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.9%
TTM · consolidated
P/E
26.0x
Q2 FY27 · consolidated
EV/EBITDA
14.1x
Q2 FY27 · consolidated
EBITDA MARGIN
13.9%
TTM · consolidated
NET PROFIT MARGIN
8.2%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27